Welcome to the CSL Behring Australia Newsroom

Media Contact:

Christina Hickie
CSL Behring Australia
Senior Manager, Communications
Phone: +61 429 609 762

First SCIg Approved for CIDP
17 Sep 2018 Company

HIZENTRA, the First Subcutaneous Immunoglobulin (SCIg) Approved for CIDP

World Haemophilia Day
17 Apr 2018 Company

CSL Behring Marks World Haemophilia Day by Shipping Bleeding Disorders Medicines to the World Federation of Haemophilia

Patient Enrolled in CSL112 Clinical Trial
23 Mar 2018 Company

The AEGIS-II trial will enrol more than 17,000 patients from approximately 1,000 medical centers around the world.

Making Forbes’ Top Global Employers List
20 Mar 2018 Company

Global biotech leader rated at no. 42 for patient focus, innovation and sustainable growth

New National Fractionation Agreement
11 Dec 2017 Company

CSL Behring today announced that it has signed an agreement with the National Blood Authority, representing all Australian governments, to continue to provide the community with a world-class and secure supply of plasma-derived therapies manufactured in Australia.

Expansion of CSL Biotech Facility
07 Dec 2017 Company

CSL today officially opened a new AUD$230 million advanced manufacturing facility at its CSL Behring site in Broadmeadows with the assistance of Victorian Minister for Industry and Employment, Ben Carroll, MP.

To see a full list of CSL Behring's news release archives, please visit our global site.

Want to know about how we are sharing stories of biotech's promise? Peruse "Vita" on our global website.

Visit Vita